William Blair reaffirmed their buy rating on shares of CELYAD SA/ADR (NASDAQ:CYAD) in a report released on Friday, August 23rd, AnalystRatings.com reports.
“We believe that the data readouts in the second half of the year will shed light into the clinical improvements with the Optimab process, allogeneic platform, and the impact of the preconditioning regimen at potentially clinically relevant doses with an eye toward selecting a Phase II (potentially registration enabling) study regimen in 2020. Celyad in June presented updated data from dose level 3 (3e9 cells given in three biweekly infusions) and initial data from cohort 10 (1e9 cells at a dense schedule of three CY AD-01 weekly infusions) of the THINK study at the European Hematology Association (EHA) 2019 meeting (EHA With CY AD-01 Dense Schedule and Preconditioning Regimens).”,” the firm’s analyst commented.
A number of other research firms have also issued reports on CYAD. Piper Jaffray Companies reduced their target price on shares of CELYAD SA/ADR from $41.00 to $25.00 and set an overweight rating on the stock in a report on Friday, July 5th. Zacks Investment Research lowered shares of CELYAD SA/ADR from a buy rating to a hold rating in a report on Wednesday, July 17th. HC Wainwright restated a buy rating and issued a $48.00 target price (down from $52.00) on shares of CELYAD SA/ADR in a report on Friday, July 5th. Finally, ValuEngine upgraded shares of CELYAD SA/ADR from a hold rating to a buy rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $29.00.
NASDAQ:CYAD opened at $12.20 on Friday. The firm has a market cap of $120.94 million, a price-to-earnings ratio of -3.07 and a beta of 1.19. The company has a current ratio of 3.98, a quick ratio of 5.36 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average is $12.69 and its two-hundred day moving average is $17.48. CELYAD SA/ADR has a 12-month low of $10.19 and a 12-month high of $31.23.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley increased its stake in shares of CELYAD SA/ADR by 24.9% during the 2nd quarter. Morgan Stanley now owns 12,473 shares of the company’s stock valued at $143,000 after acquiring an additional 2,488 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of CELYAD SA/ADR by 2.7% during the 2nd quarter. Victory Capital Management Inc. now owns 690,181 shares of the company’s stock valued at $7,917,000 after acquiring an additional 17,850 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of CELYAD SA/ADR by 69.6% during the 4th quarter. Millennium Management LLC now owns 90,597 shares of the company’s stock valued at $1,645,000 after acquiring an additional 37,171 shares during the last quarter. 7.23% of the stock is owned by institutional investors.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company’s lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Featured Article: How Do You Make Money With Penny Stocks?
Receive News & Ratings for CELYAD SA/ADR Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CELYAD SA/ADR and related companies with MarketBeat.com’s FREE daily email newsletter.